Herbal Monograph
Mucuna
Mucuna pruriens (L.) DC.
Fabaceae (Leguminosae)
Dopaminergic nervine and Ayurvedic rejuvenative that enhances neurological fu...
Overview
Plant Description
Vigorous annual or short-lived perennial herbaceous climbing vine, growing 3-18 m in length. Stems slender, twining, densely pubescent when young, becoming somewhat woody at the base in older plants. Leaves alternate, trifoliolate (three leaflets); leaflets ovate to elliptic, 6-15 cm long, 4-12 cm wide, with the terminal leaflet slightly larger than the laterals; upper surface sparsely pubescent, lower surface densely silky-pubescent; stipels present. Inflorescence an axillary pendulous raceme, 15-30 cm long, bearing numerous flowers. Flowers papilionaceous (butterfly-shaped), 2.5-3.5 cm long, dark purple to bluish-purple (occasionally white or lavender in cultivated varieties); calyx campanulate, densely pubescent; standard (banner petal) shorter than the wings and keel. Pods oblong-curved, 5-10 cm long, 1-2 cm wide, densely covered with orange-brown to silvery irritant trichomes (stinging hairs) that cause intense pruritus on skin contact — hence the specific epithet 'pruriens.' Each pod contains 4-6 seeds. Seeds ovoid to ellipsoid, 1-1.9 cm long, 0.8-1.3 cm wide, smooth, hard, variable in color from black, dark brown, mottled brown to white or cream (depending on variety); hilum prominent, surrounded by a pale ridge. Root system extensive, with a primary taproot and spreading lateral roots; roots bear nitrogen-fixing nodules (Rhizobium/Bradyrhizobium symbiosis).
Habitat
Tropical and subtropical forests, forest margins, thickets, riverbanks, roadsides, and disturbed areas. Thrives in warm, humid conditions. Grows in a wide range of tropical soil types from sandy loams to lateritic clays, preferring well-drained, fertile soils but tolerating poor or acidic soils. Optimal growth in temperatures of 20-35 degrees Celsius with annual rainfall of 1000-2500 mm. Sensitive to frost. Found from sea level to approximately 1500 m elevation in tropical regions.
Distribution
Native to tropical Africa and southern/southeastern Asia (India, Sri Lanka, Malaysia, Indonesia, Philippines, China). Now pantropical in distribution — widely naturalized throughout Central and South America, the Caribbean, tropical Africa, Southeast Asia, and Oceania. Centers of traditional medicinal use include the Indian subcontinent (where it has the longest documented history of use), West Africa (Nigeria, Ghana, Cameroon), and Central America. Cultivated commercially in India, Brazil, Ghana, Honduras, Guatemala, and other tropical countries for both medicinal and agricultural purposes.
Parts Used
Seeds (Mucunae semen)
Preferred: Dried seed powder (churna); standardized seed extract (often standardized to 15-20% L-DOPA); decoction of seeds in milk (Ayurvedic preparation); hydroalcoholic extract
The seeds are the primary medicinal part and the most extensively studied. Seeds contain the highest concentration of L-DOPA (3.6-6% by dry weight in wild varieties, sometimes reported up to 7-9% in some analyses), which is the principal bioactive constituent. Seeds are used in Ayurvedic medicine (as Kapikacchu or Atmagupta churna), in African traditional medicine, and in modern dietary supplement formulations. Quality assessment focuses on L-DOPA content, which varies significantly by variety (wild vs. cultivated), geographic origin, harvest time, and processing method. The Indian Pharmacopoeia (2018) includes specifications for Mucuna pruriens seed, including L-DOPA content as a quality marker. Seeds also contain significant protein (20-29%), lipids (6-16%), fiber, and minerals, making them nutritionally valuable after appropriate processing to reduce L-DOPA and anti-nutritional factors.
Root (Mucunae radix)
Preferred: Dried root powder; root decoction
Used in certain Ayurvedic and African traditional formulations. The root has been traditionally employed as a nervine tonic, aphrodisiac, and for urinary complaints. Root contains L-DOPA and related compounds but at lower concentrations than seeds. Less studied pharmacologically than the seed. In Ayurveda, root decoction is sometimes prescribed for Vata disorders, nervous debility, and as a Vajikara (aphrodisiac).
Trichomes (pod hairs)
Preferred: Raw trichomes mixed with honey or jaggery (traditional anthelmintic application only)
The irritant trichomes (stinging hairs) from the pod surface have a specific traditional use as an anthelmintic (anti-parasitic), particularly against intestinal roundworms (Ascaris) in Ayurvedic and folk medicine. The trichomes are carefully collected, mixed with honey or molasses, and administered orally. The mechanism is mechanical — the tiny barbed hairs irritate the intestinal lining and dislodge attached worms. This application is largely historical and has been supplanted by modern anthelmintics. CAUTION: External contact causes intense pruritus and dermatitis; the active irritant is mucunain, a cysteine protease.
Key Constituents
Catecholamines and catecholamine precursors
L-DOPA is the dominant active constituent and accounts for the majority of Mucuna's documented pharmacological effects. As the direct metabolic precursor to dopamine, L-DOPA from M. pruriens raises central and peripheral dopamine levels. This mechanism underpins the plant's effects on Parkinson's disease symptoms (motor improvement via nigrostriatal dopamine restoration), prolactin suppression (via tuberoinfundibular dopamine pathway), growth hormone stimulation, testosterone enhancement (via hypothalamic-pituitary modulation), mood elevation, and motivation enhancement. The Katzenschlager et al. (2004) clinical trial in Parkinson's patients demonstrated that M. pruriens seed powder produced clinical improvement comparable to standard levodopa/carbidopa with a faster onset of action and longer duration without increased dyskinesias, suggesting the presence of synergistic co-factors in the whole plant extract that modulate L-DOPA pharmacokinetics and reduce adverse effects. This 'entourage effect' is a key argument for whole-seed preparations over isolated L-DOPA.
Indoleamines and tryptamine derivatives
The indoleamine content of M. pruriens, particularly 5-HTP, adds a serotonergic complement to the primarily dopaminergic pharmacological profile. The combination of dopamine precursors (L-DOPA) and serotonin precursors (5-HTP) in a single plant source provides a broader spectrum of neurotransmitter modulation than either pathway alone. This dual monoaminergic activity may contribute to the traditional reputation of M. pruriens as a mood-enhancing and adaptogenic agent. The tryptamine derivatives, while present at low concentrations, indicate a rich indole alkaloid biosynthetic capacity in the plant.
Other alkaloids
The minor alkaloid fraction of M. pruriens seeds contributes to the phytochemical complexity that distinguishes the whole plant extract from isolated L-DOPA. These compounds may modulate the absorption, metabolism, or receptor-level activity of L-DOPA and contribute to the reduced side effect profile observed with whole seed preparations compared to synthetic levodopa. Further pharmacological characterization of these minor alkaloids is needed.
Irritant compounds (trichomes)
The irritant trichome compounds are relevant to handling precautions rather than therapeutic applications of the seeds. Mucunain-containing trichomes were traditionally used as a mechanical anthelmintic, but this application is largely obsolete. In seed preparations, trichome material should be absent. The pruritogenic properties are of pharmacological interest for understanding itch mechanisms but are not therapeutically exploited in modern practice.
Lectins and anti-nutritional factors
Lectins and anti-nutritional factors are relevant to food-level consumption and safety considerations rather than therapeutic activity. Proper processing of seeds for medicinal preparations reduces these factors. Standardized extracts typically have negligible anti-nutritional factor content. These compounds underscore the importance of using properly processed seed material for medicinal preparations rather than consuming raw seeds.
Nutritional constituents
The nutritional density of M. pruriens seeds — particularly their high protein, mineral (iron, zinc), and CoQ10 content — may contribute to the traditional Ayurvedic classification of the plant as a Rasayana (rejuvenative) and Balya (strength-promoting) agent. The overall nutritional profile supports the use of whole seed preparations as a tonic, complementing the specific pharmacological effects of L-DOPA and other bioactive constituents. Natarajan et al. (2012) provide a comprehensive review of the nutritional and phytochemical composition across Mucuna varieties.
Herbal Actions
The defining pharmacological action of M. pruriens, driven by its high L-DOPA content. L-DOPA crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, directly increasing central dopamine availability. This mechanism distinguishes M. pruriens from most other herbal nervines, which typically act through GABAergic, serotonergic, or adaptogenic pathways. The dopaminergic action underpins clinical effects in Parkinson's disease (Katzenschlager et al. 2004), prolactin suppression, growth hormone modulation, and subjective improvements in motivation, mood, and cognitive drive. Unlike synthetic levodopa, whole seed preparations appear to have a more favorable pharmacokinetic profile with reduced dyskinesias, possibly due to co-occurring constituents that modulate L-DOPA absorption and metabolism.
[4, 7, 12]M. pruriens demonstrates neuroprotective activity through multiple mechanisms beyond simple dopamine replacement. In animal models of Parkinson's disease, M. pruriens seed extract has shown the ability to: (1) restore endogenous dopamine, norepinephrine, and serotonin levels in the substantia nigra and striatum; (2) reduce oxidative stress markers (lipid peroxidation, protein carbonyl formation); (3) increase mitochondrial complex I activity; (4) restore antioxidant enzyme levels (superoxide dismutase, catalase, glutathione peroxidase); and (5) reduce neuroinflammatory markers. Manyam et al. (2004) demonstrated that M. pruriens cotyledon powder was significantly more effective than equivalent doses of synthetic L-DOPA in restoring brain monoamine levels and reducing oxidative damage in a rodent model of parkinsonism, suggesting neuroprotective activity beyond what can be attributed to L-DOPA content alone.
[7, 12, 13]One of the most celebrated traditional applications, classified in Ayurveda as a premier Vajikarana (aphrodisiac/virility-enhancing) herb. Modern research supports effects on male reproductive function through multiple mechanisms: (1) dopamine-mediated enhancement of libido and sexual motivation; (2) significant improvement of semen quality parameters (sperm concentration, motility, morphology) in infertile men (Shukla et al. 2009, Ahmad et al. 2008); (3) reduction of oxidative stress in seminal plasma; (4) modulation of reproductive hormones (increased testosterone and luteinizing hormone, decreased follicle-stimulating hormone and prolactin). The aphrodisiac effect is attributed primarily to the dopaminergic action (dopamine is a key neurotransmitter in sexual arousal and reward pathways) combined with antioxidant protection of reproductive tissues.
[1, 5, 6, 10]M. pruriens demonstrates adaptogenic properties in its ability to modulate the hypothalamic-pituitary-adrenal (HPA) axis and reduce markers of physiological stress. Shukla et al. (2009) demonstrated significant reductions in serum cortisol and psychological stress markers in infertile men treated with M. pruriens seed powder (5 g/day for 3 months). The plant also improved seminal plasma antioxidant status and lipid peroxide levels, indicating enhanced resistance to oxidative stress. In Ayurvedic classification, M. pruriens is considered a Rasayana (rejuvenative) that enhances overall resistance to disease and promotes longevity. The adaptogenic action is likely mediated through dopaminergic modulation of the HPA axis, antioxidant activity, and enhancement of mitochondrial function.
[1, 5]Traditionally classified in Ayurveda as Balya (strength-promoting) and Brimhana (tissue-nourishing). The anabolic reputation is supported by evidence of increased testosterone levels in infertile and stressed men (Shukla et al. 2009; Ahmad et al. 2008), stimulation of growth hormone release (dopamine-mediated, via inhibition of somatostatin), and the high protein and mineral content of the seeds. Some preliminary studies in resistance-trained men have examined effects on body composition and exercise performance, with mixed results. The anabolic classification should be understood in the Ayurvedic sense of tissue-building and strengthening rather than as equivalent to anabolic steroids.
[1, 5, 6]Prevents or slows oxidative damage to cells
M. pruriens seed extracts demonstrate significant antioxidant activity in vitro and in vivo. Multiple studies in infertile men have shown that M. pruriens supplementation reduces seminal plasma lipid peroxide levels, restores antioxidant enzyme activity (superoxide dismutase, catalase, glutathione), and reduces protein oxidation. Neuroprotective studies have shown reduction of oxidative stress markers in brain tissue. The antioxidant activity is attributed to the phenolic content (L-DOPA itself is a phenolic compound with antioxidant properties), flavonoids, and other polyphenolic constituents. The antioxidant action may contribute to both the neuroprotective and spermatogenic effects.
[5, 6, 12]Reduces serum prolactin levels through dopaminergic inhibition of prolactin secretion from the anterior pituitary. Dopamine is the primary physiological inhibitor of prolactin release (acting via D2 receptors on lactotroph cells). By increasing central dopamine via L-DOPA, M. pruriens suppresses prolactin secretion. This has clinical relevance in hyperprolactinemia-associated infertility and in the secondary endocrine effects of prolactin reduction (elevated prolactin suppresses GnRH, LH, and testosterone). Shukla et al. (2009) demonstrated significant reduction of serum prolactin in infertile men treated with M. pruriens.
[5, 10]The irritant pod trichomes have a long history of use as a mechanical anthelmintic, particularly in Ayurvedic and West African folk medicine, for intestinal roundworms (Ascaris lumbricoides, Ancylostoma). The barbed trichomes, administered orally mixed with honey or molasses, physically irritate the intestinal mucosa and dislodge attached parasites. This is a mechanical rather than pharmacological action. The practice is largely obsolete with the availability of modern anthelmintics but is documented in the Ayurvedic Pharmacopoeia of India and classical Ayurvedic texts. The seeds themselves do not possess significant anthelmintic activity.
[1, 3]Therapeutic Indications
Nervous System
Parkinson's disease (adjunctive therapy)
The most rigorously studied clinical application. Katzenschlager et al. (2004) conducted a randomized, double-blind, crossover clinical trial in 8 Parkinson's patients comparing single doses of M. pruriens seed powder (at two dose levels containing 15 mg/kg and 30 mg/kg of L-DOPA) to standard synthetic levodopa/carbidopa (200/50 mg). The 30 mg/kg M. pruriens dose produced comparable motor improvement (UPDRS scores) to synthetic levodopa/carbidopa with significantly faster onset of action (mean 34.6 min vs. 68.4 min, p=0.021) and significantly longer duration of effect without an increase in dyskinesias. Earlier open-label studies by Manyam and colleagues demonstrated sustained improvement over weeks of treatment. The Ayurvedic Pharmacopoeia of India lists Kapikacchu for Kampavata (tremor disorder/parkinsonism). M. pruriens should be used as adjunctive or complementary therapy under neurological supervision, not as a replacement for established Parkinson's pharmacotherapy without medical guidance.
[1, 4, 7, 12]Neuroprotection and neurodegenerative disease support
Preclinical evidence demonstrates broad neuroprotective activity. In MPTP-induced and 6-OHDA-induced rodent models of parkinsonism, M. pruriens seed extract significantly restored nigrostriatal dopamine levels, reduced oxidative damage (lipid peroxidation, protein carbonyls), increased mitochondrial complex I activity, and restored antioxidant enzyme systems. Manyam et al. (2004) showed that the neuroprotective effect was significantly greater than that of equivalent L-DOPA alone, indicating the presence of synergistic neuroprotective factors in the whole seed. Dhanasekaran et al. (2008) demonstrated that M. pruriens seed extract protected dopaminergic neurons from L-DOPA-induced toxicity in vitro, suggesting the whole seed may be safer than isolated L-DOPA for long-term use. Human clinical data on neuroprotection are limited to the motor improvement studies in Parkinson's patients.
[7, 12, 13]Depression and low motivation (dopamine-related)
Traditional Ayurvedic use for conditions characterized by low mood, lack of motivation, anhedonia (inability to experience pleasure), and mental fatigue — symptoms consistent with low dopaminergic tone. The dopaminergic action of L-DOPA provides a pharmacological rationale for mood enhancement. Some clinical studies on infertile men noted improvements in psychological stress and well-being scores alongside hormonal improvements (Shukla et al. 2009). However, no dedicated clinical trials for major depressive disorder have been published. M. pruriens may be most relevant for 'dopaminergic depression' characterized by apathy, anhedonia, and psychomotor retardation rather than serotonergic depression characterized by anxiety and rumination. Use in clinical depression should be under professional supervision.
[1, 5]Reproductive System
Male infertility (oligospermia, asthenospermia)
Multiple clinical trials have demonstrated significant improvements in semen quality parameters with M. pruriens supplementation. Shukla et al. (2009) treated 75 infertile men with M. pruriens seed powder (5 g/day for 3 months) and found significant improvements in sperm concentration (+31.3%), motility (+43.1%), and morphology. Seminal plasma antioxidant enzymes were restored and lipid peroxide levels reduced. Similar findings were reported by Ahmad et al. (2008) in a study of 60 infertile men, with significant improvements in sperm count, motility, and biochemical markers (citric acid, inositol, fructose, lipid peroxides, glutathione). Hormonal improvements included increased testosterone and LH, and decreased FSH and prolactin. The mechanism involves: (1) antioxidant protection of spermatozoa from oxidative damage, (2) hormonal optimization (increased testosterone, reduced prolactin), and (3) possible direct effects on spermatogenic tissue. M. pruriens is indicated for male subfertility/infertility particularly when associated with oxidative stress, hyperprolactinemia, or stress-related hormonal disruption.
[5, 6, 10]Low libido and erectile dysfunction
Traditional Ayurvedic Vajikarana (aphrodisiac) use supported by pharmacological rationale: dopamine is centrally involved in sexual desire, arousal, and reward pathways. Increased dopamine availability via L-DOPA enhances libido through mesolimbic reward circuit activation. Testosterone elevation further supports sexual function. Hyperprolactinemia is a recognized cause of low libido and erectile dysfunction in men; M. pruriens reduces prolactin via dopaminergic mechanisms. While no large-scale RCTs specifically targeting sexual dysfunction have been published, improvements in sexual function have been noted as secondary outcomes in the male infertility studies. The strong Ayurvedic traditional evidence for this indication spans centuries, with M. pruriens being one of the most prominent Vajikarana dravyas in classical texts including Charaka Samhita and Sushruta Samhita.
[1, 5, 10]Female reproductive support and fertility
While the majority of clinical research has focused on male fertility, M. pruriens has traditional use for female reproductive health in Ayurveda. Classified as beneficial for Shukra dhatu (reproductive tissue) irrespective of gender. Some Ayurvedic practitioners use it for conditions including anovulation, PCOS (polycystic ovary syndrome) with elevated prolactin, and as a general reproductive tonic for women. The hypoprolactinemic effect may have clinical relevance for women with prolactin-related anovulation. However, published clinical data specifically addressing female reproductive outcomes are very limited, and use in women should be under professional guidance, particularly given the potent dopaminergic activity which could affect menstrual cycling and fertility through hypothalamic-pituitary-gonadal axis modulation.
[1]Endocrine System
Hyperprolactinemia and prolactin-related disorders
Dopamine is the primary physiological inhibitor of prolactin release from the anterior pituitary (acting via D2 receptors on lactotroph cells). M. pruriens, via its L-DOPA-derived dopamine, suppresses prolactin secretion. Clinical data from male infertility studies consistently show significant reduction in serum prolactin levels with M. pruriens supplementation (Shukla et al. 2009, Ahmad et al. 2008). This has clinical implications for both men and women with hyperprolactinemia-associated symptoms including galactorrhea, amenorrhea, infertility, and sexual dysfunction. The prolactin-lowering effect is mechanistically identical to that of pharmaceutical dopamine agonists (cabergoline, bromocriptine) but achieved through a natural precursor pathway. Patients currently on pharmaceutical dopamine agonists should not add M. pruriens without medical supervision due to risk of additive dopaminergic effects.
[5, 6, 10]Testosterone optimization and hormonal support in men
Multiple clinical studies in infertile men have demonstrated significant increases in serum testosterone with M. pruriens supplementation. Shukla et al. (2009) reported testosterone increases across all treatment groups (normospermic stressed, oligospermic, asthenozoospermic). Ahmad et al. (2008) confirmed testosterone elevation alongside increased LH. The mechanism likely involves: (1) dopaminergic stimulation of GnRH pulsatility, leading to increased LH secretion and testicular testosterone synthesis; (2) reduction of prolactin (elevated prolactin inhibits GnRH and testosterone); (3) reduction of cortisol (which inhibits testosterone synthesis); (4) possible direct antioxidant protection of Leydig cells. The testosterone-elevating effect appears most pronounced in men with baseline hormonal disruption (stressed, infertile) rather than healthy eugonadal men. Effects in healthy young men with normal hormonal profiles are less well-documented.
[5, 6, 10]Growth hormone stimulation
Dopamine stimulates growth hormone (GH) release from the anterior pituitary via D2 receptor activation on somatotroph cells and through inhibition of somatostatin secretion. L-DOPA infusion has been used clinically as a GH provocation test. Oral M. pruriens supplementation has been shown to acutely increase serum GH levels. This GH-stimulating effect may contribute to the traditional Ayurvedic classification of M. pruriens as a Rasayana (rejuvenative) and anabolic agent. The GH elevation is transient (physiological pulsatile release pattern) rather than sustained pathological elevation.
[1, 5]Musculoskeletal System
Muscle weakness and physical debility (Balya application)
M. pruriens is classified in Ayurveda as Balya (strength-promoting) and is traditionally used for conditions of physical weakness, muscle wasting, and debility. The rationale includes: (1) high protein and nutritional content of the seeds providing building material for muscle tissue; (2) testosterone elevation supporting muscle protein synthesis; (3) growth hormone stimulation supporting tissue repair and anabolism; (4) adaptogenic stress reduction allowing improved recovery. Some modern interest exists in sports nutrition contexts for these properties, though large-scale clinical trials in athletes are limited. In Ayurvedic practice, M. pruriens is often combined with Ashwagandha (Withania somnifera) and Shatavari (Asparagus racemosus) in formulas for Dhatukshaya (tissue depletion) and Karshya (emaciation).
[1, 10]Joint pain and rheumatic conditions (traditional)
Traditional Ayurvedic use for Vata-type joint pain and stiffness. M. pruriens is considered Vata-shamaka (Vata-pacifying) due to its warm, heavy, oily qualities. The warm virya and oily guna are particularly relevant to Vata-type musculoskeletal conditions characterized by dryness, cracking, and stiffness. Some in vitro and animal studies suggest anti-inflammatory activity of M. pruriens seed extracts. In traditional practice, the seeds are often prepared as a decoction in milk or as a powder mixed with ghee for musculoskeletal complaints.
[1, 3]Energetics
Temperature
warm
Moisture
moist
Taste
Tissue States
cold/depression, wind/tension (Vata)
In Ayurvedic energetics, M. pruriens (Kapikacchu) is classified as: Rasa (taste) — Madhura (sweet), Tikta (bitter); Guna (quality) — Guru (heavy), Snigdha (oily/unctuous); Virya (potency) — Ushna (warm); Vipaka (post-digestive effect) — Madhura (sweet). It reduces Vata and Kapha doshas while potentially increasing Pitta in excess. The sweet rasa and vipaka, combined with the heavy and oily gunas, make it a tissue-nourishing (Brimhana) herb that builds Shukra dhatu (reproductive tissue), Mamsa dhatu (muscle tissue), and Majja dhatu (nervous tissue). The warm virya provides the metabolic activation necessary for tissue building and counters the cold, dry, light qualities of Vata imbalance. In Western energetic terms, M. pruriens can be understood as a warming, moistening, building tonic — appropriate for conditions of depletion, coldness, dryness, and nervous debility (Vata-type presentations). It is less appropriate for hot, inflammatory, and Pitta-excess conditions. The dopaminergic action particularly addresses the 'cold depression' tissue state where there is lack of motivation, drive, pleasure, and vitality — conditions associated with low dopaminergic tone.
Traditional Uses
Ayurvedic medicine (Indian subcontinent)
- Kampavata (tremor disorders, corresponding to parkinsonism) — seed powder in milk decoction
- Vajikarana (aphrodisiac therapy) — one of the premier Vajikarana dravyas for enhancing virility, libido, and semen quality
- Rasayana (rejuvenative therapy) — for promoting strength, vitality, and longevity
- Shukra dhatu kshaya (depletion of reproductive tissue) — to build and strengthen Shukra dhatu
- Vata Vyadhi (Vata disorders) — nervous system disorders, tremor, weakness, debility, pain
- Krimiroga (worm infestation) — pod trichomes mixed with honey as mechanical anthelmintic
- Unmada (mental disorders) — certain classical preparations for mental instability
- Apasmara (seizure disorders) — mentioned in some classical texts as a supportive agent
"M. pruriens (Kapikacchu, Atmagupta, Kevanch) holds a prominent position in classical Ayurvedic literature spanning over two millennia. It is mentioned extensively in the foundational texts: Charaka Samhita (c. 300 BCE-200 CE) lists it as a Vajikarana dravya in the Chikitsasthana (therapeutics section); Sushruta Samhita (c. 300 BCE-500 CE) describes it for Vata disorders and as a Rasayana; and Ashtanga Hridaya by Vagbhata (c. 600 CE) includes it in numerous formulations. Bhavaprakash Nighantu (16th century) provides detailed descriptions of its properties: sweet and bitter taste, warm potency, sweet post-digestive effect, heavy and unctuous qualities, and its actions of pacifying Vata and Kapha while being Vajikarana and Balya. The Ayurvedic Pharmacopoeia of India (Government of India, 2001) includes a monograph for Kapikacchu (Mucuna pruriens) seed, specifying its use in Kampavata (tremor/parkinsonism), as a Vajikarana, and listing quality standards. The specific application in Kampavata (tremor disease) is remarkable as it predates the Western identification of dopamine deficiency in Parkinson's disease by centuries — Ayurvedic physicians empirically discovered the clinical efficacy of a dopamine precursor-rich plant for a dopamine-deficiency disorder through systematic clinical observation."
African traditional medicine
- Snakebite treatment — seed or root preparations applied topically and taken internally in West and Central Africa
- Aphrodisiac and virility enhancement — seed preparations in Nigeria, Ghana, Cameroon, and elsewhere
- Scorpion sting treatment — traditional application in some regions
- Intestinal parasites — pod hairs mixed with food substances as anthelmintic
- General tonic and strengthening agent — seed preparations for physical weakness
- Mumps and male reproductive complaints — various preparations across West Africa
- Diarrhea and dysentery — root and seed decoctions in some ethnomedicinal traditions
"M. pruriens is widely distributed across tropical Africa and has a substantial ethnomedicinal history on the continent. In Nigerian traditional medicine, the seeds are used as an aphrodisiac and for male sexual dysfunction. In Ghanaian traditional medicine, seed preparations are employed as a tonic and for snakebite treatment. The plant is known by numerous vernacular names across African languages, reflecting its widespread recognition and use. The anthelmintic use of pod trichomes is common across West and Central Africa, paralleling the Ayurvedic application. In some East African traditions, root decoctions are used for abdominal pain and reproductive complaints. The pan-African distribution and broad ethnomedicinal use indicate independent development of knowledge about this plant's medicinal properties, separate from the Ayurvedic tradition. WHO surveys of traditional medicine in newly independent states have documented the widespread use of M. pruriens across multiple cultural traditions."
Central and South American traditional medicine
- Coffee substitute (seeds roasted as 'Nescafe') — particularly in Guatemala and Honduras
- General tonic and nutritive food — processed seeds consumed for strength
- Aphrodisiac — seed preparations in some Caribbean and Central American folk traditions
- Kidney complaints — root decoction in some traditional systems
- Fever — leaf preparations in folk medicine
"In Central America, particularly Guatemala, Honduras, and Mexico, M. pruriens (known locally as 'nescafe,' 'pica-pica,' or 'frijol terciopelo') is commonly cultivated as a cover crop, green manure, and food source. The seeds are roasted and used as a coffee substitute — a practice so common that the vernacular name 'nescafe' directly references this use. This roasting process substantially reduces L-DOPA content while producing a palatable beverage. In Brazilian traditional medicine, the plant (known as 'feijao-da-florida' or 'mucuna') has some use as a tonic and for kidney complaints. The Mesoamerican use of M. pruriens is more agricultural and nutritional than strictly medicinal, reflecting the plant's dual identity as both food and medicine."
[11]
Modern Research
Mucuna pruriens versus synthetic levodopa in Parkinson's disease
Randomized, double-blind, controlled crossover clinical trial comparing single doses of M. pruriens seed powder (containing 15 mg/kg and 30 mg/kg of L-DOPA) to standard synthetic levodopa/carbidopa (200/50 mg) and placebo in 8 patients with Parkinson's disease and levodopa-responsive motor fluctuations.
Findings: The 30 mg/kg M. pruriens preparation produced motor improvement (UPDRS part III scores) comparable to standard levodopa/carbidopa (200/50 mg). Critically, M. pruriens at the 30 mg/kg dose showed significantly faster onset of action (mean 34.6 minutes vs. 68.4 minutes for L-DOPA/carbidopa, p=0.021) and significantly longer duration of 'on' time without increasing peak dyskinesias. Plasma L-DOPA levels achieved with M. pruriens were comparable to those from synthetic levodopa. The 15 mg/kg dose was less effective. The authors concluded that the rapid onset and prolonged effect suggest that co-occurring substances in the seed powder may enhance L-DOPA bioavailability or modulate its pharmacokinetics.
Limitations: Very small sample size (n=8). Single-dose comparison (not chronic use). Short observation period. No peripheral decarboxylase inhibitor (carbidopa) was co-administered with the M. pruriens preparation. The study does not address long-term efficacy, safety, or disease modification.
[4]
Neuroprotective effects in experimental parkinsonism models
A series of preclinical studies examining the neuroprotective effects of M. pruriens seed powder in rodent models of chemically-induced parkinsonism, comparing whole seed preparations to equivalent doses of synthetic L-DOPA.
Findings: Manyam et al. (2004) demonstrated that M. pruriens cotyledon powder significantly restored endogenous levels of dopamine, norepinephrine, and serotonin in the nigrostriatal tract of mice with MPTP-induced parkinsonism — an effect that was significantly greater than that of equivalent doses of synthetic L-DOPA. The seed powder also reduced lipid peroxidation products and restored mitochondrial complex I activity in brain tissue. In a separate study, Dhanasekaran et al. (2008) showed that M. pruriens aqueous extract protected dopaminergic neurons from L-DOPA-induced cytotoxicity in cell culture, suggesting that constituents in the whole seed may mitigate the pro-oxidant toxicity of L-DOPA when administered in isolation. Earlier work by Hussian and Manyam (1997) provided the initial preclinical evidence of anti-parkinsonian activity and neuroprotection.
Limitations: Preclinical (animal and cell culture) data only. Direct extrapolation to human neuroprotection is uncertain. Different dosing and formulations across studies. Long-term neuroprotective effects in humans have not been established. The specific neuroprotective constituents beyond L-DOPA have not been fully identified.
Effects on semen quality and reproductive hormones in infertile men
Clinical study examining the effects of M. pruriens seed powder (5 g/day for 3 months) on semen quality parameters, seminal plasma biochemistry, and reproductive hormones in 75 men undergoing infertility screening, compared to 75 age-matched fertile men.
Findings: Treatment with M. pruriens significantly improved semen parameters: sperm concentration, motility, and morphology all improved significantly (p<0.001). Seminal plasma antioxidant enzymes (superoxide dismutase, catalase, glutathione) were significantly increased, while lipid peroxide (malondialdehyde) levels were significantly reduced. Hormonal changes included: significantly increased testosterone (p<0.001) and LH (p<0.001); significantly decreased FSH (p<0.001) and prolactin (p<0.001). Psychological stress (measured by cortisol) was also significantly reduced. Treatment restored semen parameters toward normal fertile reference values.
Limitations: Not randomized or blinded. No placebo control group (comparison was to untreated fertile controls). Relatively short treatment period (3 months). Single center. The study population was specifically infertile men — results may not generalize to fertile men or other populations. The 5 g/day dose is relatively high.
[5]
Mucuna pruriens and semen quality in infertile men (Ahmad et al.)
Clinical study evaluating the effects of M. pruriens seed powder (5 g/day for 3 months) on seminal plasma metabolites, lipid peroxidation, antioxidant vitamins, corrected seminal fructose, and hormonal profile in 60 infertile men compared to 60 fertile controls.
Findings: M. pruriens treatment significantly improved sperm motility and count. Seminal plasma levels of citric acid, inositol, and fructose were corrected toward normal fertile values. Lipid peroxide levels were significantly reduced while vitamins A, C, and E and glutathione levels increased. Serum testosterone and LH increased significantly while FSH and prolactin decreased. The authors concluded that M. pruriens improves fertility by combating oxidative stress in seminal plasma and correcting the underlying hormonal imbalance.
Limitations: Same limitations as Shukla et al. — non-randomized, non-blinded, no placebo group. Single center. Population limited to infertile men.
[6]
Comprehensive review of Mucuna pruriens pharmacology and clinical potential
Systematic review article examining the phytochemistry, pharmacology, and clinical evidence for M. pruriens across all documented therapeutic applications including neurological, reproductive, and metabolic effects.
Findings: The review identified L-DOPA as the principal active constituent responsible for the majority of pharmacological effects. Clinical evidence was assessed as strongest for Parkinson's disease (Katzenschlager et al. 2004) and male infertility (multiple controlled trials). Preclinical evidence was strong for neuroprotection, antioxidant activity, anti-diabetic effects, and anti-venom properties. The review highlighted the pharmacological advantage of whole seed preparations over isolated L-DOPA, noting reduced side effects, faster onset, and longer duration of action. Safety profile was assessed as generally favorable at standard doses with appropriate precautions. Key gaps identified included the need for larger randomized controlled trials, long-term safety data, dose-response studies, and identification of specific synergistic co-factors in the whole seed.
Limitations: Narrative review (not systematic meta-analysis). Quality of included primary studies was variable. Publication bias may affect the evidence base. The review covered a very broad range of indications, limiting depth on any single topic.
Anti-diabetic and metabolic effects
Preclinical studies examining the hypoglycemic and anti-diabetic effects of M. pruriens seed extracts in animal models of diabetes mellitus.
Findings: Multiple animal studies have demonstrated significant blood glucose-lowering effects of M. pruriens seed extracts in alloxan-induced and streptozotocin-induced diabetic rodent models. Mechanisms may include: enhancement of insulin secretion, improvement of insulin sensitivity, inhibition of alpha-glucosidase, and antioxidant protection of pancreatic beta cells. D-chiro-inositol, a compound detected in M. pruriens seeds, has independent insulin-sensitizing activity. Some studies have also shown improvement in lipid profile parameters (reduced total cholesterol, LDL, triglycerides; increased HDL) in diabetic animal models.
Limitations: All data are preclinical (animal models). No published human clinical trials specifically for diabetes. Effective doses in animals may not translate directly to human dosing. The relationship between L-DOPA content and hypoglycemic effect is not fully elucidated — some studies suggest non-L-DOPA constituents contribute to the anti-diabetic activity.
Preparations & Dosage
seed-powder (churna)
Strength: Whole seed powder; L-DOPA content typically 3.6-6% depending on variety and processing. A 5 g dose of powder with 5% L-DOPA content provides approximately 250 mg L-DOPA.
Dried M. pruriens seeds are roasted or toasted lightly (traditional method to reduce anti-nutritional factors and improve palatability), then ground to a fine powder. In Ayurvedic practice, the powder (churna) is often administered mixed with warm milk, ghee (clarified butter), or honey as an anupana (vehicle) to enhance absorption and direct the herb's action. Some preparations use raw dried seed powder without roasting, which retains higher L-DOPA content. The powder has a slightly nutty, somewhat bitter taste.
3-6 g of seed powder per day, typically divided into 1-2 doses. The Ayurvedic Pharmacopoeia of India specifies 3-6 g as the standard dose range. Clinical trials for male infertility used 5 g/day. Start at the lower end (3 g) and increase based on response and tolerance.
Once or twice daily. Traditional Ayurvedic use is often twice daily (morning and evening). For sleep and reproductive effects, evening dosing may be preferred. For energy and motivation, morning dosing may be preferred.
Traditional use: 1-3 months or longer as a Rasayana. Clinical trials for infertility used 3-month treatment periods. For Parkinson's support: ongoing under medical supervision. Periodic reassessment of response and tolerance is recommended. Extended continuous use at higher doses warrants monitoring for potential dopaminergic side effects.
Not recommended for children. Insufficient safety data in pediatric populations. The potent dopaminergic activity makes pediatric use inadvisable without specialist supervision.
The most traditional Ayurvedic preparation. Whole seed powder provides the full spectrum of constituents including L-DOPA, 5-HTP, alkaloids, protein, minerals, and CoQ10. The whole seed preparation has shown advantages over isolated L-DOPA in clinical studies (faster onset, longer duration, fewer dyskinesias in Parkinson's — Katzenschlager et al. 2004). Administration with milk or ghee is traditional and may improve absorption of lipophilic constituents. Roasting reduces L-DOPA content by approximately 30-50% depending on temperature and duration; if high L-DOPA content is desired (e.g., for Parkinson's support), raw powder or lightly processed seed may be preferred.
Standardized Extract
Strength: Standardized to 15%, 20%, or 40% L-DOPA (most common). DER variable depending on extraction process and concentration method.
Commercially prepared extracts standardized to a defined L-DOPA content (typically 15%, 20%, or 40% L-DOPA by weight). Available as capsules or loose powder. These concentrated extracts allow precise L-DOPA dosing and are the form most commonly available in Western dietary supplement markets. Follow manufacturer's specific dosing guidelines, which vary by extract concentration.
Varies by L-DOPA standardization. General guideline: 200-600 mg of a 15% L-DOPA extract (providing 30-90 mg L-DOPA) per day. For a 40% extract: 100-300 mg per day. Some products targeting Parkinson's support may use higher doses under medical guidance. Total daily L-DOPA from the supplement should typically not exceed 300 mg without medical supervision.
1-2 times daily. Take with food to reduce nausea.
Assess response after 4-8 weeks. Long-term use should be periodically reassessed.
Not recommended for children.
Standardized extracts provide the most consistent and reproducible L-DOPA dosing but may lack some of the synergistic co-factors present in whole seed preparations. The Katzenschlager et al. (2004) Parkinson's study used whole seed powder (not a standardized extract), so the evidence for synergistic benefits specifically applies to whole seed preparations. When selecting a commercial product, look for third-party testing for L-DOPA content, heavy metals, and microbial contamination. Highly concentrated extracts (40% L-DOPA) are essentially approaching pharmaceutical-grade L-DOPA and require greater caution regarding drug interactions and adverse effects.
decoction-in-milk (Ksheerapaka)
Strength: 3-6 g seed powder per 200 mL milk
The traditional Ayurvedic Ksheerapaka preparation: add 3-6 g of M. pruriens seed powder to 200 mL of milk and 200 mL of water. Simmer gently on low heat until the volume is reduced to approximately 200 mL (the water portion evaporates). Strain and drink warm. Honey or raw sugar may be added for taste after cooling to drinking temperature. Some formulations include additional herbs such as Ashwagandha or Shatavari.
One preparation (200 mL) once or twice daily. Typically taken in the evening or before bed for Vajikarana (aphrodisiac) purposes, or in the morning for energizing and tonic purposes.
Once or twice daily.
Traditionally used for 1-3 months as a Rasayana course. May be repeated after a break.
Not recommended for children.
The Ksheerapaka (milk decoction) is a classical Ayurvedic preparation method considered particularly appropriate for Vajikarana and Rasayana applications. Milk is chosen as the vehicle (anupana) because: (1) it is itself considered a Rasayana and Vajikarana in Ayurveda; (2) the fat content of milk may enhance absorption of lipophilic constituents; (3) milk's sweet, cooling, and unctuous qualities balance the warming potency of M. pruriens; (4) milk proteins may buffer some of the gastrointestinal effects of L-DOPA. This preparation is considered superior to simple water decoction in the Ayurvedic tradition for reproductive and rejuvenative applications.
hydroalcoholic-tincture
Strength: 1:5, 50-60% ethanol (dried seed)
Macerate dried, powdered M. pruriens seeds in ethanol-water menstruum at 1:5 ratio in 50-60% ethanol. Macerate for 4-6 weeks with regular agitation. Press and filter. L-DOPA is water-soluble, so both aqueous and hydroalcoholic extractions capture this primary constituent. The hydroalcoholic preparation also extracts alkaloids and other intermediate-polarity compounds.
2-5 mL up to 2-3 times daily.
1-3 times daily.
4-12 weeks initially. Reassess response.
Not recommended for children.
Tinctures are less commonly used than powder or standardized extract preparations for M. pruriens but offer a convenient liquid dosage form. The L-DOPA content per milliliter of tincture is lower than in powder or concentrated extract preparations, which may limit efficacy for conditions requiring higher L-DOPA doses (e.g., Parkinson's support). Tinctures may be more suitable for lower-dose applications such as mood support and mild hormonal modulation.
[11]
Capsule / Powder
Strength: Varies by product. Whole seed powder or standardized extract (15-40% L-DOPA). Quality control for L-DOPA content is essential.
Dried, powdered M. pruriens seeds or standardized extract in vegetable or gelatin capsules. Many commercial products are available. Choose products with clearly stated L-DOPA standardization and third-party testing certification (NSF, USP, or equivalent).
Whole seed powder capsules: 500-1000 mg per capsule, 3-6 capsules daily (to achieve 3-6 g total). Standardized extract capsules: follow manufacturer's guidelines based on L-DOPA content. Typical: 200-500 mg of standardized extract, 1-2 capsules daily.
1-2 times daily, with food.
Assess response after 4-8 weeks. Ongoing use as indicated.
Not recommended for children.
Capsules provide convenient, taste-neutral dosing and are the most common format in Western supplement markets. When choosing between whole seed powder capsules and standardized extract capsules, consider the clinical evidence: the Parkinson's study (Katzenschlager et al. 2004) used whole seed powder, while the male infertility studies (Shukla et al. 2009, Ahmad et al. 2008) also used whole seed powder. Standardized extracts offer more precise L-DOPA dosing but may lack the full complement of synergistic co-factors. Quality control should conform to Indian Pharmacopoeia standards for L-DOPA content where applicable.
Safety & Interactions
Class 2b
Not to be used during lactation (AHPA Botanical Safety Handbook)
Contraindications
M. pruriens seeds contain L-DOPA (levodopa), the same compound found in pharmaceutical Parkinson's medications. Concurrent use with synthetic levodopa/carbidopa or other dopaminergic Parkinson's drugs (pramipexole, ropinirole, rotigotine, amantadine, selegiline, rasagiline) without medical supervision could result in additive or unpredictable dopaminergic effects including severe dyskinesias, psychosis, orthostatic hypotension, or serotonin-dopamine imbalance. Patients on Parkinson's medications who wish to use M. pruriens MUST do so under the direct supervision of their treating neurologist, with careful dose adjustment of both agents.
MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid, and the selective MAO-B inhibitors selegiline and rasagiline) block the enzymatic degradation of dopamine and other monoamines. Adding L-DOPA from M. pruriens to MAOI therapy could result in dangerous accumulation of dopamine and other catecholamines, leading to hypertensive crisis, serotonin syndrome, or severe cardiovascular events. This is a well-established contraindication in L-DOPA pharmacology. M. pruriens should not be taken within 14 days of MAOI use.
Individuals with documented allergy to M. pruriens or with severe legume allergy should avoid all preparations. The seeds contain lectins and proteins that may be allergenic in sensitized individuals. Contact dermatitis from pod trichomes is common and represents a separate (non-immunological) irritant mechanism.
L-DOPA crosses the placenta and enters breast milk. Dopaminergic agents have potential teratogenic effects and can suppress prolactin-mediated lactation. M. pruriens is classified in Ayurveda as contraindicated in pregnancy (Garbhini parivarjya). No human safety data during pregnancy or lactation exist. The potent dopaminergic and hormonal effects make this a firm contraindication.
L-DOPA is converted to dopamine, which at high levels can increase heart rate and cause cardiac arrhythmias. Orthostatic hypotension is a known side effect of L-DOPA therapy. Patients with severe cardiovascular disease should not use M. pruriens without cardiological supervision.
Dopamine excess is implicated in the pathophysiology of psychosis and schizophrenia (the dopamine hypothesis of schizophrenia). M. pruriens, by increasing central dopamine levels, could theoretically exacerbate psychotic symptoms. Patients with schizophrenia or schizoaffective disorder are typically treated with dopamine receptor antagonists (antipsychotics); M. pruriens could antagonize this treatment. Contraindicated in active psychosis and in patients on antipsychotic medications.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Levodopa/carbidopa (Sinemet, Stalevo, Madopar) and other levodopa-containing preparations (Anti-Parkinson dopaminergic agents) | major | Additive L-DOPA/dopamine levels. M. pruriens provides exogenous L-DOPA that adds to the L-DOPA from pharmaceutical preparations. Unlike pharmaceutical levodopa/carbidopa combinations, M. pruriens does not contain a peripheral decarboxylase inhibitor, resulting in different L-DOPA pharmacokinetics. |
| Monoamine oxidase inhibitors — MAO-A inhibitors (phenelzine, tranylcypromine, isocarboxazid, moclobemide) and MAO-B inhibitors (selegiline, rasagiline, safinamide) (MAO inhibitors) | major | MAO inhibitors block the enzymatic degradation of dopamine, norepinephrine, serotonin, and other monoamines. Adding L-DOPA from M. pruriens increases substrate for monoamine synthesis while MAO inhibition prevents their breakdown, leading to dangerous accumulation of catecholamines and serotonin. |
| Dopamine receptor antagonists (haloperidol, chlorpromazine, risperidone, olanzapine, quetiapine, aripiprazole, metoclopramide, domperidone) (Antipsychotics / Dopamine antagonists) | moderate | Pharmacological antagonism. Dopamine receptor antagonists block the post-synaptic receptors that dopamine (derived from M. pruriens-supplied L-DOPA) acts upon. The two classes have directly opposing mechanisms. |
| Antihypertensive medications (all classes) (Antihypertensives) | moderate | L-DOPA/dopamine can cause vasodilation and hypotension. Additive blood pressure-lowering effects when combined with antihypertensive medications. |
| Hypoglycemic agents (insulin, metformin, sulfonylureas, GLP-1 agonists) (Anti-diabetic medications) | moderate | M. pruriens has demonstrated hypoglycemic effects in animal models. The mechanism may involve enhancement of insulin secretion, improvement of insulin sensitivity, and/or alpha-glucosidase inhibition. |
| Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine) (Tricyclic antidepressants) | moderate | TCAs inhibit reuptake of norepinephrine and serotonin. Combined with the monoaminergic effects of L-DOPA and 5-HTP from M. pruriens, there is potential for excessive monoaminergic stimulation. |
| Anesthetics (general and local) (Anesthetic agents) | moderate | L-DOPA and its metabolites can sensitize the myocardium to catecholamine-induced arrhythmias, which may interact with volatile anesthetic agents and sympathomimetic vasoconstrictors used in local anesthesia. |
Pregnancy & Lactation
Pregnancy
unsafe
Lactation
unsafe
PREGNANCY: Contraindicated during pregnancy. L-DOPA crosses the placental barrier. Dopaminergic agents have demonstrated teratogenic effects in some animal studies, and the hormonal effects of M. pruriens (prolactin suppression, testosterone modulation) are inappropriate during pregnancy. No human pregnancy safety data exist. The Ayurvedic tradition classifies M. pruriens as Garbhini parivarjya (to be avoided in pregnancy). LACTATION: Contraindicated during breastfeeding. L-DOPA and dopamine suppress prolactin, which is essential for milk production (prolactin is the primary lactogenic hormone). M. pruriens could significantly reduce milk supply. Additionally, L-DOPA and its metabolites may pass into breast milk, exposing the infant to dopaminergic compounds. Some traditional Ayurvedic texts conversely mention M. pruriens as a galactagogue in very low doses — this appears contradictory to the pharmacological evidence and should not be relied upon.
Adverse Effects
References
Monograph Sources
- [1] Government of India, Ministry of Health and Family Welfare, Department of AYUSH. The Ayurvedic Pharmacopoeia of India, Part I, Volume I: Kapikacchu (Mucuna pruriens). The Controller of Publications, New Delhi (2001) : 56-57
- [2] World Health Organization. WHO Monographs on Medicinal Plants Commonly Used in the Newly Independent States (NIS). World Health Organization, Geneva (2010)
- [3] Kirtikar KR, Basu BD. Indian Medicinal Plants, Volume I (Second Edition): Mucuna pruriens. Lalit Mohan Basu, Allahabad (1935) : 802-806
Clinical Studies
- [4] Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry (2004) ; 75 : 1672-1677 . DOI: 10.1136/jnnp.2003.028761 . PMID: 15548480
- [5] Shukla KK, Mahdi AA, Ahmad MK, Jaiswar SP, Shankwar SN, Tiwari SC. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertil Steril (2009) ; 92 : 1934-1940 . DOI: 10.1016/j.fertnstert.2008.09.045 . PMID: 18973898
- [6] Ahmad MK, Mahdi AA, Shukla KK, Islam N, Jaiswar SP, Ahmad S. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertil Steril (2008) ; 90 : 627-635 . DOI: 10.1016/j.fertnstert.2007.07.1341 . PMID: 18001720
- [7] Hussian G, Manyam BV. Mucuna pruriens proves more effective than L-DOPA in Parkinson's disease animal model. Phytother Res (1997) ; 11 : 419-423 . DOI: 10.1002/(SICI)1099-1573(199709)11:6<419::AID-PTR120>3.0.CO;2-Q
Traditional Texts
- [8] Charaka (Agnivesha, revised by Charaka and Dridhabala). Charaka Samhita: Chikitsasthana — Vajikarana adhyaya (Section on Aphrodisiacs). Chaukhambha Sanskrit Sansthan, Varanasi (modern editions) (-300)
- [9] Bhavamishra. Bhavaprakash Nighantu: Guduchyadi Varga — Kapikacchu (Atmagupta). Chaukhambha Bharati Academy, Varanasi (modern editions) (1550)
- [10] Singh AP, Sarkar S, Tripathi M, Rajender S. Mucuna pruriens and its major constituent L-DOPA recover spermatogenic loss by combating ROS, loss of mitochondrial membrane potential and apoptosis. PLoS One (2013) ; 8 : e54655 . DOI: 10.1371/journal.pone.0054655 . PMID: 23382934
Pharmacopeias & Reviews
- [11] Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of Mucuna pruriens. J Tradit Complement Med (2012) ; 2 : 331-339 . DOI: 10.1016/S2225-4110(16)30119-5 . PMID: 24716148
- [12] Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res (2004) ; 18 : 706-712 . DOI: 10.1002/ptr.1514 . PMID: 15478206
- [13] Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV. Neuroprotective mechanisms of ayurvedic antidementia botanical Mucuna pruriens. Neurochem Res (2008) ; 33 : 1990-2005 . DOI: 10.1007/s11064-008-9678-x . PMID: 18404371
- [14] Natarajan K, Narayanan N, Ravichandran N. Review on Mucuna — the wonder plant. Int J Pharm Sci Rev Res (2012) ; 17 : 86-93
- [15] Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2018: Mucuna pruriens seed. Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Ghaziabad (2018)
Last updated: 2026-03-01 | Status: published
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.